With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the CD8+ to Treg cell ratio and promoting tumor rejection. Antibodies with improved FcγR binding profiles drove superior anti-tumor responses and survival. In patients with advanced melanoma, response to ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such activity only appeared relevant in the context of inflamed tumors, explaining the modest response rates observed in the clinical setting. Our data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.
Keywords: CTLA-4; Fc-gamma receptors; IgG subclass; antibody-dependent cell-mediated cytotoxicity; immune checkpoints; immune regulatory antibodies; ipilimumab; regulatory T cell depletion; tremelimumab; tumor immunotherapy.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.